Hugo™ Versus daVinci™ Robot-Assisted Radical Prostatectomy: 1-Year Propensity Score-Matched Comparison of Functional and Oncological Outcomes
Journal of Clinical Medicine · 16.11.2024 · 13 (22) · 6910
DOI: 10.3390/jcm13226910 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.11.2024. Verfasst von Carlo Gandi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: A comprehensive comparison of intraoperative, oncological, and functional outcomes of RARP performed with different robotic surgical platforms is critically needed. Our aim is to compare the oncological and functional outcomes of RARP performed using the novel Hugo™ RAS system with those from the daVinci system, the reference standard, at a high-volume robotic center, with an extended follow-up period (one year).
Methods
We analyzed the data of 400 patients undergoing RARP ± pelvic lymph node dissection between 2021 and 2023, using propensity score (PS) matching to correct for treatment selection bias. All procedures were performed by three surgeons with HugoTM RAS or daVinci. This analysis extends the follow-up period to 1 year, focusing on specific functional and oncological outcomes, building on our previous 3-month evaluation of perioperative outcomes. The primary outcome was the trifecta rate, defined as freedom from biochemical recurrence, continence, and erectile function recovery. Secondary outcomes included detailed assessments of oncological outcomes (PSA levels) and functional outcomes (continence and erectile function).
Results
The propensity score-matched cohort included 99 matched pairs (198 patients), balanced for all covariates. No significant differences were found in trifecta rates between the two platforms at 1-year follow-up (Hugo: 25.25%, daVinci: 27.27%, p = 0.743). Both groups showed improved trifecta rates when considering only nerve-sparing procedures (Hugo: 36.84%, daVinci: 35.59%, p = 0.889). Continence rates were similar (Hugo: 87.9%, daVinci: 89.9%, p = 0.327), as were the undetectable PSA rates (Hugo: 92.9%, daVinci: 88.8%, p = 0.158). Also, the erectile function recovery rate did not differ significantly between the groups.
Conclusions
This is the first study comparing 1-year functional and oncological outcomes of RARP performed with Hugo™ RAS and daVinci surgical robotic systems using PS matching. Functional and oncological outcomes of RARP were comparable between the two robotic platforms. These findings confirm that the transition to the Hugo™ platform does not compromise surgical proficiency or patient outcomes, even if further long-term studies are necessary to confirm these results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
- Department of Medicine and Translational Surgery, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
- Department of Life Sciences and Public Health, Section of Hygiene, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
- Department of Woman and Child Health and Public Health-Public Health Area, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
- Department of Urology, Ospedale Isola Tiberina-Gemelli Isola, 00168 Rome, Italy.
ORCID-Profile: Carlo Gandi, Filippo Marino, Eros Scarciglia, Filippo Gavi, Francesco Rossi, Seyed Koosha Moosavi, Giuseppe Palermo, Marco Racioppi, Nicolò Lentini, Emilio Sacco
Zitieren
APA
Gandi, C., Marino, F., Totaro, A., Scarciglia, E., Presutti, S., Bellavia, F., Bientinesi, R., Gavi, F., Rossi, F., Moosavi, S. K., Palermo, G., Racioppi, M., Lentini, N., Pastorino, R., & Sacco, E. (2024). Hugo™ Versus daVinci™ Robot-Assisted Radical Prostatectomy: 1-Year Propensity Score-Matched Comparison of Functional and Oncological Outcomes. Journal of Clinical Medicine, 13(22), 6910. https://doi.org/10.3390/jcm13226910
Vancouver
Gandi C, Marino F, Totaro A, Scarciglia E, Presutti S, Bellavia F, et al. Hugo™ Versus daVinci™ Robot-Assisted Radical Prostatectomy: 1-Year Propensity Score-Matched Comparison of Functional and Oncological Outcomes. Journal of Clinical Medicine. 2024;13(22):6910. doi:10.3390/jcm13226910
BibTeX
@article{Gandi2024,
author = {Gandi, Carlo and Marino, Filippo and Totaro, Angelo and Scarciglia, Eros and Presutti, Simona and Bellavia, Fabrizio and Bientinesi, Riccardo and Gavi, Filippo and Rossi, Francesco and Moosavi, Seyed Koosha and Palermo, Giuseppe and Racioppi, Marco and Lentini, Nicolò and Pastorino, Roberta and Sacco, Emilio},
title = {Hugo™ Versus daVinci™ Robot-Assisted Radical Prostatectomy: 1-Year Propensity Score-Matched Comparison of Functional and Oncological Outcomes},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {22},
pages = {6910},
doi = {10.3390/jcm13226910}
}
EUVIMED